Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 481

1.

Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.

Kramkowski K, Leszczynska A, Mogielnicki A, Chlopicki S, Fedorowicz A, Grochal E, Mann B, Brzoska T, Urano T, Motterlini R, Buczko W.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2149-57. doi: 10.1161/ATVBAHA.112.253989. Epub 2012 Jul 5.

2.

Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3).

Soni H, Jain M, Mehta AA.

Thromb Res. 2011 Jun;127(6):551-9. doi: 10.1016/j.thromres.2011.02.009. Epub 2011 Mar 4.

PMID:
21376373
3.

Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors.

Chlopicki S, Lomnicka M, Fedorowicz A, Grochal E, Kramkowski K, Mogielnicki A, Buczko W, Motterlini R.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Jun;385(6):641-50. doi: 10.1007/s00210-012-0732-4. Epub 2012 Feb 25.

4.

CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule.

Motterlini R, Sawle P, Hammad J, Bains S, Alberto R, Foresti R, Green CJ.

FASEB J. 2005 Feb;19(2):284-6. Epub 2004 Nov 19.

5.

Comparison of the effects of CORM-2, CORM-3 and CORM-A1 on coagulation in human plasma.

Nielsen VG, Garza JI.

Blood Coagul Fibrinolysis. 2014 Dec;25(8):801-5. doi: 10.1097/MBC.0000000000000146.

PMID:
25058038
6.

Aliskiren inhibits experimental venous thrombosis in two-kidney one- clip hypertensive rats.

Hermanowicz JM, Hermanowicz A, Buczko P, Leszczynska A, Tankiewicz-Kwedlo A, Mogielnicki A, Buczko W.

Thromb Res. 2013 Jan;131(1):e39-44. doi: 10.1016/j.thromres.2012.11.001. Epub 2012 Nov 20.

PMID:
23174623
7.

Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.

Chlopicki S, Olszanecki R, Marcinkiewicz E, Lomnicka M, Motterlini R.

Cardiovasc Res. 2006 Jul 15;71(2):393-401. Epub 2006 Mar 22.

8.

Positive inotropic effects of carbon monoxide-releasing molecules (CO-RMs) in the isolated perfused rat heart.

Musameh MD, Fuller BJ, Mann BE, Green CJ, Motterlini R.

Br J Pharmacol. 2006 Dec;149(8):1104-12. Epub 2006 Oct 23.

9.

Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.

Nielsen VG, Kirklin JK, George JF.

Blood Coagul Fibrinolysis. 2009 Sep;20(6):448-55. doi: 10.1097/MBC.0b013e32832f4335.

PMID:
19581800
10.

Cerebroprotective effects of the CO-releasing molecule CORM-A1 against seizure-induced neonatal vascular injury.

Zimmermann A, Leffler CW, Tcheranova D, Fedinec AL, Parfenova H.

Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2501-7. Epub 2007 Jul 13.

11.

The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.

Nielsen VG.

Blood Coagul Fibrinolysis. 2010 Sep;21(6):584-7. doi: 10.1097/MBC.0b013e32833cea13.

PMID:
20683324
12.

[Study of exogenous carbon monoxide-releasing molecules 2 on endotoxin/lipopolysaccharide-induced abnormal activation of platelets of healthy human donors].

Liu D, Zhuang M, Zhang J, Chen J, Sun B.

Zhonghua Shao Shang Za Zhi. 2015 Oct;31(5):354-60. Chinese.

PMID:
26714404
13.

Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).

Xiong J, Fang W, Fang W, Bai L, Huo J, Kong Y, Yunman L.

J Pharm Pharmacol. 2009 Jan;61(1):89-94. doi: 10.1211/jpp/61.01.0012.

PMID:
19126301
14.

A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.

Szemraj J, Stankiewicz A, Rozmyslowicz-Szermińska W, Mogielnicki A, Gromotowicz A, Buczko W, Oszajca K, Bartkowiak J, Chabielska E.

Thromb Haemost. 2007 Jun;97(6):1037-45.

PMID:
17549308
15.

Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.

Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.

J Cardiovasc Pharmacol. 1997 Aug;30(2):261-72.

PMID:
9269956
16.

Carbon monoxide-releasing molecule-2 decreases fibrinolysis in vitro and in vivo in the rabbit.

Nielsen VG, Arkebauer MR, Wasko KA, Malayaman SN, Vosseller K.

Blood Coagul Fibrinolysis. 2012 Jan;23(1):104-7. doi: 10.1097/MBC.0b013e32834ea012.

PMID:
22143252
17.

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.

Pehrsson S, Johansson K, Kjaer M, Elg M.

Thromb Haemost. 2010 Dec;104(6):1242-9. doi: 10.1160/TH09-10-0744. Epub 2010 Aug 30.

PMID:
20806126
18.

Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo.

Pircher J, Fochler F, Czermak T, Mannell H, Kraemer BF, Wörnle M, Sparatore A, Del Soldato P, Pohl U, Krötz F.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2884-91. doi: 10.1161/ATVBAHA.112.300627. Epub 2012 Sep 27.

19.

Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits.

Nielsen VG, Chawla N, Mangla D, Gomes SB, Arkebauer MR, Wasko KA, Sadacharam K, Vosseller K.

Blood Coagul Fibrinolysis. 2011 Dec;22(8):756-9. doi: 10.1097/MBC.0b013e32834c7412.

PMID:
22008906
20.

Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation.

Rand ML, Wang H, Pluthero FG, Stafford AR, Ni R, Vaezzadeh N, Allison AC, Kahr WH, Weitz JI, Gross PL.

J Thromb Haemost. 2012 Jun;10(6):1109-19. doi: 10.1111/j.1538-7836.2012.04716.x.

Items per page

Supplemental Content

Write to the Help Desk